Cargando…
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study
SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with few patients carrying driver mutations in the gene encoding for epidermal growth factor receptor (EGFR). Advances in translational research have established EGFR tyrosine kinase inhibitors (T...
Autores principales: | Mountzios, Giannis, Koumarianou, Anna, Bokas, Alexandros, Mavroudis, Dimitrios, Samantas, Epaminondas, Fergadis, Evangelos Georgios, Linardou, Helena, Katsaounis, Panagiotis, Athanasiadis, Elias, Karamouzis, Michalis V., Pentheroudakis, George, Lampaki, Sofia, Froudarakis, Marios E., Perdikouri, Eleni-Isidora A., Somarakis, Alvertos, Papageorgiou, Foteini, Paparepa, Zoe, Nikolaou, Aristeidis, Syrigos, Konstantinos N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268841/ https://www.ncbi.nlm.nih.gov/pubmed/34202063 http://dx.doi.org/10.3390/cancers13133172 |
Ejemplares similares
-
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios, Giannis, et al.
Publicado: (2021) -
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020) -
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
por: Mountzios, Giannis, et al.
Publicado: (2022) -
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017) -
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)